Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679494 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8773327 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1784260 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9251636 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28351585 | 0.84 | FKBP1A (0.67) | FKBP1APREP | |
| SCHEMBL13148433 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13413549 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13099455 | 0.84 | FKBP1A (0.60) | FKBP1APREP | |
| SCHEMBL27553714 | 0.84 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12869918 | 0.84 | FKBP1A (0.60) | FKBP1APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026090584-A2 | METHODS OF TREATING PERIPHERAL NERVOUS SYSTEM MYELINATION CONDITIONS | Artery Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20030153785-A1 | Method for preserving quaternary ammonium salt | TOKUYAMA CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| US-6458948-B1 | MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC | TOKUYAMA CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1178043-A1 | METHOD FOR STORING QUATERNARY AMMONIUM SALT | TOKUYAMA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1085000-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT | TOKUYAMA CORPORATION (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-5965556-A | KETO-ACID AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR INHIBITING THE ACTIVITY OF SERINE PROTEASE OR THIOL PROTEASE BY ADMINISTERING THE DERIVATIVE TO A MAMMAL; ALZHEIMER'S DISEASE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5756763-A | ENZYME INHIBITOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0709373-A1 | NOVEL PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | FKBP1A 3885/4885PREP 2276/4885NPC1 3565/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | FKBP1A 3776/4885PREP 2443/4885NPC1 2481/4885 |
| US-20030153785-A1 | Method for preserving quaternary ammonium salt | NHERF1, ASH1L, ATP6V1B1 | FKBP1A 1410/4885PREP 1471/4885NPC1 1782/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | FKBP1A 1555/4885PREP 380/4885NPC1 4205/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | FKBP1A 2340/4885PREP 324/4885NPC1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.